|
|
Profile
|
Delegates :
Hiroshi Miyake |
|
Incorporated :
October 12 , 2017 |
Paid in Capital :
90 Million yen |
Employees :
22 人 |
Address :
2-26-1, Muraoka-Higashi, Fujisawa KANAGAWA
〒2510012
|
TEL/FAX :
817045504443 / |
URL：
https://www.chordiatherapeutics.com/en/index.html |
Attachment :
|
Mission/Background :
Chordia Therapeutics is a clinical stage biotech, focusing on an RNA Deregulation Stress approach as a novel therapeutic strategy using our pipeline CTX-712, CLK inhibitor currently in Phase 1/2 in U.S., CTX-439, CDK12 inhibitor in the finishing IND-enabling studies, preclinical GCN2 inhibitor as well as additional undisclosed discovery programs for addressing the unmet medical needs of patients. |
|
Technology & Business
|
Chordia is a spin-out company from Japanese big Pharma that has building a comprehensive drug discovery and development capabilities and collaborating with passionate scientists all over the world. The company is building a pipeline of small molecule anti-cancer drug candidates by focusing on RNA deregulation stress, which has been identified as a new characteristic of cancer. With the mission of " We are passionate about delivering first-in-class cancer drugs to patients from Japan," the company's vision for 2030 is " To be an R&D oriented pharmaceutical company based in Japan." The company will actively utilize collaboration with various partners, including academia, CDMOs, and distributors etc.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
CLK inhibitor, CTX-712
|
Phase1/2
|
Inhibition of CLK causes abnormal RNA to accumulate and load the RNA deregulation stress.
|
Priority expedited approval in Japan and the U.S. after Japanese Phase I confirms response in patients with R/R AML.
|
MALT1 inhibitor, CTX-177
|
Phase1
|
CTX-177 shows anticancer activity by inhibiting MALT1 and suppressing the transcription factor NF-κB
|
Exclusive development and marketing rights have been granted to Ono, and clinical trials are currently underway in the US
|
CDK12 inhibitor, CTX-439
|
Preclinical
|
Inhibits mRNA transcription by blocking CDK12, thereby loading and killing cancer cells
|
Preparations are currently underway for the start of Phase I, including the manufacture of investigational drug.
|
GCN2 inhibitor, CRD-1968099
|
Preclinical
|
GCN2 inhibitors cause abnormalities in tRNA transport, causing abnormal tRNA to accumulate and load cancer cell death.
|
Preclinical studies are underway to initiate Phase I.
|
New Program
|
Discovery
|
|
Preclinical studies are underway to initiate Phase I.
|
|
Highlights
|
Please refer to the following website for the most recent progress.
https://www.chordiatherapeutics.com/en/news.html
|
|
Alliance strategy
|
In order to bring novel anti-cancer drug to patients as quickly as possible, we are actively seeking joint research and development, licensing, and other strategic business partnerships.
|
|
|